¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Host Cell Factor C1"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
  • amacrine cell
    ¹«Ãà»è¼¼Æ÷
  • ameboid cell
    ¾Æ¸Þ¹Ù¸ð¾ç¼¼Æ÷
  • anaplastic large cell lymphoma
    ¿ªÇü¼ºÅ«¼¼Æ÷¸²ÇÁÁ¾
  • basal cell
    ¹Ù´Ú¼¼Æ÷, ±âÀú¼¼Æ÷
  • basal cell adenoma
    ¹Ù´Ú¼¼Æ÷»ùÁ¾, ±âÀú¼¼Æ÷¼±Á¾
  • basal cell carcinoma
    ¹Ù´Ú¼¼Æ÷¾ÏÁ¾, ±âÀú¼¼Æ÷¾ÏÁ¾
  • basal cell epithelioma
    ¹Ù´Ú¼¼Æ÷»óÇÇÁ¾, ±âÀú¼¼Æ÷»óÇÇÁ¾
  • basal cell nevus
    ¹Ù´Ú¼¼Æ÷¸ð¹Ý, ±âÀú¼¼Æ÷¸ð¹Ý
  • basal cell nevus syndrome
    ¹Ù´Ú¼¼Æ÷¸ð¹ÝÁõÈıº, ±âÀú¼¼Æ÷¸ð¹ÝÁõÈıº
  • basket cell
    ¹Ù±¸´Ï¼¼Æ÷
  • basophilic cell
    È£¿°±â¼¼Æ÷
  • basosquamous cell acanthoma
    ¹Ù´ÚÆíÆò¼¼Æ÷°¡½Ã¼¼Æ÷Á¾, ±âÀúÆíÆò±Ø¼¼Æ÷Á¾
  • basosquamous cell carcinoma
    ¹Ù´ÚÆíÆò¼¼Æ÷¾ÏÁ¾, ±âÀúÆíÆò¼¼Æ÷¾ÏÁ¾
  • beta cell
    º£Å¸¼¼Æ÷
  • bipolar cell
    µÎ±Ø¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
  • argentaffin cell
    ģũ·ÒÀº¼¼Æ÷
  • argyrophilic cell
    ÀºÄ£È­¼¼Æ÷
  • asexual cell
    ¹«¼º¼¼Æ÷
  • basal cell adenoma
    ±âÀú¼¼Æ÷»ùÁ¾, ¹Ù´Ú¼¼Æ÷¾ÏÁ¾
  • basosqumaous cell acanthoma
    ±âÀúÆíÆò¼¼Æ÷°¡½Ã¼¼Æ÷Á¾
  • cell-associated antibody
    ¼¼Æ÷ºÎÂøÇ×ü
  • cell-bound antibody
    (¢¡cell-fixed antibody) ¼¼Æ÷°áÇÕÇ×ü
  • cell-fixed antibody
    ¼¼Æ÷°áÇÕÇ×ü
  • clear cell acanthoma
    Åõ¸í¼¼Æ÷°¡½Ã¼¼Æ÷Á¾
  • clear cell adenocarcinoma
    Åõ¸í¼¼Æ÷»ù¾ÏÁ¾
  • crescent cell anemia
    Ãʽ´ÞÀûÇ÷±¸ºóÇ÷
  • helper cell activity
    µµ¿ò¼¼Æ÷´É, Á¶·Â¼¼Æ÷´É
  • islet cell adenoma
    ¼¶¼¼Æ÷»ùÁ¾
  • large cell acanthoma
    Å«¼¼Æ÷°¡½Ã¼¼Æ÷Á¾
  • red cell aplasia
    ÀûÇ÷±¸¹«Çü¼º
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
  • LE cell phenomenon
    LE¼¼Æ÷Çö»ó.
  • Langerhans cell
    ¶û°Ô¸£Çѽº¼¼Æ÷.
  • Langerhans cell histiocytosis
    ¶û°Ô¸£Çѽº ¼¼Æ÷ Á¶Á÷±¸Áõ
  • Langerhans cell histiocytosis
    ¶û°Ô¸£Çѽº¼¼Æ÷Á¶Á÷±¸Áõ
  • Langerhans giant cell
    ¶û±×Çѽº°Å¼¼Æ÷
  • Langhans giant cell
    ¶û±×Çѽº°Å´ë¼¼Æ÷
  • Leydig cell
    ·¹À̵ðÈ÷ ¼¼Æ÷
  • Leydig cell adenoma
    ·¹À̵ðÈ÷¼¼Æ÷¼±Á¾
  • Leydig cell tumor
    ·¹À̵ðÈ÷¼¼Æ÷Á¾¾ç
  • Leydig s cell
    ¶óÀ̵ðÈ÷¼¼Æ÷.
  • MCH => mean cell hemoglobin
    Æò±ÕÀûÇ÷±¸Ç÷»ö¼Ò
  • MCHC => mean cell hemogiooln concentration
    Æò±ÕÀûÇ÷±¸Ç÷»ö¼Ò³óµµ
  • MCV => mean cell volume
    Æò±ÕÀûÇ÷±¸¿ëÀû
  • Merkel cell carcinoma
    ¸Þ¸£Ä̼¼Æ÷ ¾Ï(Á¾)
  • Mikulicz cell
    ¹ÌÄð¸®Áî ¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
  • factor B
    B ÀÎÀÚ
  • factor B
    BÀÎÀÚ
  • factor D
    D ÀÎÀÚ
  • factor D
    DÀÎÀÚ
  • factor H
    H ÀÎÀÚ
  • factor H, B1H
    HÀÎÀÚ
  • factor I
    I ÀÎÀÚ
  • factor I
    IÀÎÀÚ
  • factor II
    Á¦ II ÀÎÀÚ
  • factor IX
    Á¦ IX ÀÎÀÚ
  • factor IX transfusion
    Á¦ IX ÀÎÀÚ¼öÇ÷
  • factor IXa
    Á¦ IXaÀÎÀÚ
  • factor V
    Á¦ V ÀÎÀÚ
  • factor VII
    Á¦ VII ÀÎÀÚ
  • factor VIII antibody
    Á¦ VIII ÀÎÀÚÇ×ü
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
  • Intermitotic cell
    ºÐ¿­»çÀ̱⼼Æ÷
    [¿¾ ¿ë¾î] °£±â¼¼Æ÷
  • Epitheloid muscle cell
    »óÇǼº±ÙÀ°¼¼Æ÷
    [¿¾ ¿ë¾î] »óÇǾç±Ù¼¼Æ÷
  • Chromophilic cell
    »ö¼Òµë¼¼Æ÷
    [¿¾ ¿ë¾î] »ö¼ÒÈ£¼º¼¼Æ÷
  • Pigment cell
    »ö¼Ò¼¼Æ÷
    [¿¾ ¿ë¾î] »ö¼Ò¼¼Æ÷
  • Chromophobic cell
    »ö¼Ò¾Èµë¼¼Æ÷
    [¿¾ ¿ë¾î] »ö¼ÒÇø¼º¼¼Æ÷
  • Cell inclusions
    ¼¼Æ÷Æ÷ÇÔ¹°
    [¿¾ ¿ë¾î] ¼¼Æ÷Æ÷ÇÔ¹°
  • Purkinje cell
    ½ÉÀåÀüµµ±ÙÀ°¼¼Æ÷
    [¿¾ ¿ë¾î] ½ÉÀåÀÚ±ØÀüµµ¼¼Æ÷
  • Purkinje cell
    ½ÉÀåÀüµµ±ÙÀ°¼¼Æ÷
    [¿¾ ¿ë¾î] Ǫ¸£Å²¿¹¼¼Æ÷
  • Exocrine cell
    ¿ÜºÐºñ¼¼Æ÷
    [¿¾ ¿ë¾î] ¿ÜºÐºñ¼¼Æ÷
  • Villous muscle cell
    À¶¸ð±ÙÀ°¼¼Æ÷
    [¿¾ ¿ë¾î] À¶¸ð±Ù¼¼Æ÷
  • Chief cell
    À¸¶ä¼¼Æ÷
    [¿¾ ¿ë¾î] ÁÖ¼¼Æ÷
  • Milk secreting cell
    Á¥ºÐºñ¼¼Æ÷
    [¿¾ ¿ë¾î] À¯¼¼Æ÷
  • Purkinje cell
    Á¶·Õ¹Ú¼¼Æ÷
    [¿¾ ¿ë¾î] Purkinje¼¼Æ÷
  • Ovoid cell
    Ÿ¿ø¼¼Æ÷
    [¿¾ ¿ë¾î] ³­¿øÇü¼¼Æ÷
  • Oxyphilic cell
    È£»ê¼º¼¼Æ÷
    [¿¾ ¿ë¾î] »êÈ£¼º¼¼Æ÷
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
  • factor XIII
    ÀÎÀÚ(ì×í­) XIII
  • factor XIV
    ÀÎÀÚ(ì×í­) XIV
  • factor F
    ÀÎÀÚ(ì×í­) F
  • factor G
    ÀÎÀÚ(ì×í­) G
  • factor IF
    ÀÎÀÚ(ì×í­) IF
  • factor R
    ÀÎÀÚ(ì×í­) R
  • factor T
    ÀÎÀÚ(ì×í­) T
  • factor theory
    ÀÎÀÚ ÀÌ·Ð(ì×í­×âÖå)
  • factor X
    ÀÎÀÚ(ì×í­) X
  • factor Y
    ÀÎÀÚ(ì×í­) Y
  • fertility factor
    ¼öÁ¤ ÀÎÀÚ (áôïñì×í­)
  • F factor
    F ÀÎÀÚ(ì×í­)
  • F' factor
    F' ÀÎÀÚ(ì×í­)
  • fibrin-stabilizing factor
    ¼¶À¯¼Ò ¾ÈÁ¤È­ÀÎÀÚ(àéë«áÈäÌïÒûùì×í­)
  • Fitzgerald factor
    ÇÍÁ¦¶öµå ÀÎÀÚ(ì×í­)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 13
SCA self-care agency; severe congenital anomaly; sickle-cell anemia; single-camera autostereoscopic [ima...
SCC self-care center; sequential combination chemotherapy; services for crippled children; short-course ...
SCM Schwann cell membrane; sensation, circulation, and motion; Society of Computer Medicine; soluble cyt...
TCE T-cell enriched; tetrachlorodiphenyl ethane; trichloroethylene T-cell thymus-derived cell
TCR T-cell reactivity; T-cell receptor; T-cell rosette; thalamocortical relay; total cytoplasmic ribosom...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 13
D factor Differentiation-stimulating factor
TRAF Factor Receptor-associated factor
FVIII-vWF Factor VIII-von Willebrand Factor
Factor Xa Factor X
GM-CSF Granulocyte colony-stimulating factor , granulocyte-macrophage colony-stimulating factor
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • basal cell adenocarainoma
    ±âÀú ¼¼Æ÷ ¼±¾Ï
    ¸Å¿ì µå¹°°í ±âÀú ¼¼Æ÷ ¼±Á¾ÀÇ ¾Ç¼ºÀÌ´Ù. ¿Ü°úÀû ÀýÁ¦ ½Ã ¿¹Èİ¡ ÁÁ´Ù.
  • basal cell carcinoma
    ±âÀú ¼¼Æ÷ ¾Ï, ±âÀú ¼¼Æ÷ ¾ÏÁ¾
    1. »óÇÇÀÇ ±âÀú ¼¼Æ÷¸¦ ´àÀº ±âº» ±¸Á¶¸¦ °¡Áö´Â »óÇÇ ¼¼Æ÷ ½Å»ý¹°. À̰ÍÀº »óÇÇ ¼¼Æ÷ÀÇ ±âÀú ¼¼Æ÷, ¸ð³¶À̳ª ÇÇÁö¼±ÀÇ ¿Ü¹æ ¼¼Æ÷, ƯÈ÷ ¾È¸éÀÇ °¡¿îµ¥ 1/3¿¡¼­ ¹ß»ýÇÑ´Ù. µå¹°°Ô ÀüÀ̵ÇÁö¸¸ ±¹¼ÒÀûÀ¸·Î ħ¹üÇÑ´Ù. ±¸°­ Á¡¸·¿¡¼­´Â ¹ß»ýÇÏÁö ¾Ê´Â´Ù. Çѱ¹ÀÎ ÇǺΠ¾Ç¼º Á¾¾ç Áß °¡Àå ¸¹Àº ÇüÀÌ´Ù. ÀüÀ̰¡ Àß ¾ÈµÇ¸ç Àç¹ßÀ²ÀÌ ÀûÀº Áß°£ ¾Ç¼ºµµÀÌ´Ù. ±¸°­ÀÇ ±âÀú ¼¼Æ÷ ¸ð¹Ý ÁõÈıº°ú °ü·ÃÀÌ ÀÖ´Ù. 2. Ç¥ÇÇ ±âÀúÃþÀÇ ¾Ç¼º Á¾¾ç.
  • basal cell epithelioma
    ±âÀú ¼¼Æ÷ »óÇÇ ¾Ï, ±âÀú ¼¼Æ÷ »óÇÇÁ¾
    Áß³â ÀÌÈÄ¿¡ »ý±â±â ½±°í ±× ŹÝÀÌ ¾È¸é ÇǺο¡ ¹ß»ýÇÑ´Ù. Ãø»öÀÇ ¼Ò°áÀýÀÌ Áý»êÇÑ Á¾¾çÀ» Çü¼ºÇϴµ¥ ¹Ý±¸»óÀ¸·Î À¶±âÇÏ´Â °Í, ÆíÆòÇÑ ¹Ý»óÀÇ ÆÛÁü µî ¿©·¯ °¡ÁöÀÌ´Ù. Á¶Á÷ÇÐÀûÀ¸·Î´Â ÇǺΠǥÇÇ ±âÀú ¼¼Æ÷ÀÇ Áõ½ÄÀÌ°í ¼¼Æ÷ ºÐ¿­, ÀÌÇü¼º µîÀº °ÅÀÇ ³ªÅ¸³ªÁö ¾Ê´Â´Ù.
  • basal cell hyperplasia
    ±âÀú ¼¼Æ÷ °úÇü¼º
  • basal cell nevus
    ±âÀú ¼¼Æ÷ ¸ð¹Ý
  • basal cell papilloma
    ±âÀú ¼¼Æ÷ À¯µÎÁ¾
  • basal-cell layer
    ±âÀú ¼¼Æ÷Ãþ
  • basophilic cell
    È£¿°±â¼º ¼¼Æ÷
  • basosqumaous cell acanthoma
    ±âÀú ÆíÆò ¼¼Æ÷ ±Ø¼¼Æ÷Á¾
  • benign giant cell tumor
    ¾ç¼º °Å´ë¼¼Æ÷ Á¾¾ç
    1. °ñÀÇ ¾ç¼º °Å´ë¼¼Æ÷Á¾. °ñÀÇ ¾ç¼º Á¾¾çÀÇ Çϳª·Î ³ë¾àÀÚ¿¡°Ô ¸¹À¸¸ç ¹ß»ý ºÎÀ§´Â Àå°ü°ñÀÇ °ñ´Ü¿¡ ¸¹ÀÌ ³ªÅ¸³­´Ù. Á¶Á÷ÇÐÀûÀ¸·Î ¿øÇü, ¹æÃßÇüÀÌ ÀÖ´Ù. ¼¼Æ÷ »çÀÌ¿¡ ÆÄ°ñ¼¼Æ÷¿Í À¯»çÇÑ °Å´ë¼¼Æ÷°¡ È¥ÀçÇÑ´Ù. 2. °ÇÃÊÀÇ ¾ç¼º °Å´ë¼¼Æ÷Á¾. º»·¡ Á¾¾çÀÌ ¾Æ´Ï¸ç, °áÁ¤¼º °ÇÃÊ¿°À» °¡¸®Å°¸ç °ÇÃÊÀÇ ¼¶À¯¼º Á¶Á÷±¸Á¾¿¡ Æ÷ÇԵȴÙ.
  • beta cell tumor
    º£Å¸ ¼¼Æ÷Á¾
  • beta-cell tumor
    º£Å¸ ¼¼Æ÷ Á¾¾ç
    µµ¼¼Æ÷ Á¾¾ç Áß °¡Àå ÈçÇÑ Áúº´À¸·Î Àν¶¸° °ú´Ù ºÐºñ°¡ ÀϾ´Ù.
  • bipolar cell
    µÎ ±Ù ½Å°æ¼¼Æ÷, ½Ö±Ø ¼¼Æ÷
    µÎ °³ÀÇ µ¹±â¸¦ °¡Áø ½Å°æ¼¼Æ÷.
  • blood cell counter
    Ç÷±¸ °è¼ö±â
  • bone cell
    °ñ ¼¼Æ÷
    °ñÁ¶Á÷ÀÇ ±âº» ¼¼Æ÷. °ñ Á¶Á÷¿¡´Â µüµüÇÑ °ñ ±âÁú¾È¿¡ °ñ¼Ò°­À̶ó°í ÇÏ´Â Æ´ÀÌ ±ºµ¥±ºµ¥ ÀÖ°í, ±× ¼Ó¿¡ 1°³¾¿ÀÇ °ñ ¼¼Æ÷°¡ µé¾î ÀÖ´Ù. °ñ ¼¼Æ÷ÀÇ ÇüÅ´ °ñ¼Ò°­°ú ÀÏÄ¡ÇÏ¿© ÆíÆòÇÑ Å¸¿øÇüÀ¸·Î, ±æÀÌ´Â 15¡­27 ¥ìmÀÌ´Ù. °ñ ¼¼Æ÷´Â ´Ù¼öÀÇ °¡´Â ¿øÇüÁú µ¹±â°¡ À־, À̰ÍÀÌ ±âÁú ³»ÀÇ °ñ ¼¼°üÀ» ÅëÇÏ¿© °¡±îÀÌ ÀÖ´Â °ñ ¼¼Æ÷ÀÇ µ¹±â¿Í ÇÕÄ£´Ù. °ñ ¼¼Æ÷´Â º»·¡ °áÇÕÁ¶Á÷ÀÇ ¼¶À¯¾Æ¼¼Æ÷¿¡¼­ Çü¼ºµÇ´Â °ÍÀ¸·Î, ¸ÕÀú °ñ¾Æ¼¼Æ÷°¡ µÇ¾î, À̰ÍÀÌ ±âÁúÀ» ¸¸µé°í ÀÚ½ÅÀº ±× ±âÁú ¼Ó¿¡ µé¾î°¡ °ñ¼¼Æ÷·Î µÈ´Ù. À̰ÍÀº °ñ Á¶Á÷ÀÇ Á¦Á¶ÀÚÀ̸ç, ¼¼Æ÷ÁúÀº ¹Ì·®ÀÇ ¹ÌÅäÄܵ帮¾Æ¸¦ Æ÷ÇÔÇϰí, È£¾à¿°±â¼ºÀ» ³ªÅ¸³½´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 13
sarcoma growth factor <growth factor> Polypeptide released by sarcoma cells that promotes the growth of cells by binding to a cell surface receptor, the sarcoma cell is therefore self sufficient and independent of normal growth control.
See: growth factors.
The name is no longer commonly used.
(18 Nov 1997)
heparin binding growth factor <growth factor> Acidic fibroblast growth factor (alpha FGF, HBGF 1) and basic FGF (beta FGF, HBGF 2) are the two founder members of a family of structurally related growth factors for mesodermal or neuroectodermal cells.
Synonym: heparin binding growth factor.
Acronym: FGF
(18 Nov 1997)
properdin factor A A component of the properdin system; a hydrazine-sensitive b1-globulin (mw about 180,000), now known to be C3 (third component of complement).
(05 Mar 2000)
properdin factor b <enzyme> A glycine-rich, heat-labile beta-glycoprotein found in blood. It is a proactivator of complement 3 in the alternate pathway of complement activation. Factor b is converted by factor d to c3 convertase.
Registry number: EC 3.4.21.47
(12 Dec 1998)
properdin factor d <enzyme> A serum protein which during the alternate pathway of complement activation converts the inactive properdin factor b to c3 convertase.
Registry number: EC 3.4.21.46
(12 Dec 1998)
properdin factor E A serum protein (mw 160,000) required for activation of C3 (third component of complement) by cobra venom factor.
See: properdin system.
(05 Mar 2000)
hepatocyte growth factor <growth factor> Polypeptide mitogen originally shown to cause cell division in hepatocytes.
In the liver, the main sources of hepatocyte growth factor are nonparenchymal cells. It is now clear that hepatocyte growth factor is a mitogen for a number of cell types and it is found in many cells outside the liver, including platelets.
Hepatocyte growth factor is synthesised as a single chain precursor that is proteolytically cleaved to give a heavy chain (70 kD) and a light chain (30 kD) linked by a single disulphide bond. It contains multiple copies of the kringle domain.
However, both the single chain precursor and the two chain forms of hepatocyte growth factor are biologically active and hepatocyte growth factor is generally isolated as a mixture of the two forms. Hepatocyte growth factor also alters cell motility and is now known to be identical to scatter factor.
Acronym: HGF
(18 Nov 1997)
scatter factor A motility factor (motogen) isolated from conditioned medium in which human fibroblasts have been grown. It causes colonies of epithelial and endothelial cells, in culture, to separate into single cells that move apart i.e. They scatter. It has been shown to be identical to human hepatocyte growth factor, but it is not mitogenic for all cell types.
(18 Nov 1997)
proteinase inhibitor inducing factor See: PIIF.
(18 Nov 1997)
protein factor The factor (6.25) by which the nitrogen content of a protein is multiplied to give the amount of protein.
(05 Mar 2000)
pro-transforming growth factor-alpha processing protease <enzyme> Converts membrane-bound protgf-alpha to soluble tgf-alpha; mw 84 kD
Registry number: EC 3.4.21.-
Synonym: protgf-alpha converting enzyme, protgfalpha processing protease
(26 Jun 1999)
schwannoma derived growth factor <growth factor> A growth factor containing an EGF like domain, mitogenic for astrocytes, Schwann cells and fibroblasts.
(18 Nov 1997)
HG factor A polypeptide hormone (3485 D) secreted by the cells of the Islets of Langerhans in response to a fall in blood sugar levels. Induces hyperglycaemia. A family of structurally related peptides includes glucagon like peptides 1 & 2 (encoded by the same gene), gastric inhibitory polypeptide, secretin, vasoactive intestinal peptide, growth hormone releasing factor, pituitary adenylate cyclase activating polypeptide, exendins.
(18 Nov 1997)
x factor <biochemistry> A precursor necessary to synthesise cytochromes.
(09 Oct 1997)
psi factor A protein responsible for the specific initiation of the RNA polymerase-catalyzed reaction at the promoter sites of genes.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 13
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 13
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 13
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 13
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 13
ÅëÇÕ°Ë»ö ¿Ï·á